Dual GIP and GLP-1 receptor agonist — the first dual-agonist of its class. Active ingredient in Mounjaro (T2D) and Zepbound (weight + OSA), and in compounded preparations. ~5-day half-life enables weekly subcutaneous dosing. Manufacturer: Eli Lilly.
Pharmacology
Dual GIP and GLP-1 receptor agonist — the first dual-agonist of its class. Active ingredient in Mounjaro (T2D) and Zepbound (weight + OSA), and in compounded preparations. ~5-day half-life enables weekly subcutaneous dosing. Manufacturer: Eli Lilly.
FDA-approved indications
- Type 2 diabetes (Mounjaro) — 2022
- Chronic weight management (Zepbound) — November 2023; basis: SURMOUNT-1 (up to 22.5% weight loss)
- Moderate-to-severe OSA in adults with obesity (Zepbound) — December 2024; basis: SURMOUNT-OSA. First drug ever FDA-approved for OSA
Standard dosing
| Indication | Starting | Titration | Maintenance |
|---|---|---|---|
| T2D (Mounjaro) | 2.5 mg/wk × 4 wk | 5 → 7.5 → 10 → 12.5 → 15 mg | 5–15 mg weekly |
| Weight/OSA (Zepbound) | 2.5 mg/wk × 4 wk | 5 → 7.5 → 10 → 12.5 → 15 mg | 5, 10, or 15 mg weekly |
Side effects
- Common (>10%): nausea, diarrhea, decreased appetite, vomiting, constipation, abdominal pain
- Boxed warning: MTC and MEN-2 contraindications
Compounded availability
Compounded tirzepatide contains the same active ingredient as branded. 503B bulk pathway restricted following FDA shortage resolution (August 2024); 503A patient-specific continues. Cash-pay pricing $186–$289/mo. See NexLife for flat-rate $186/mo on 12-month plan.
See also
· Research bibliography · Drug interactions · Where to get it (compounded)